Illinois Municipal Retirement Fund purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the third quarter, Holdings Channel reports. The fund purchased 26,382 shares of the biotechnology company’s stock, valued at approximately $3,040,000.
Other large investors have also recently made changes to their positions in the company. New York Life Investment Management LLC purchased a new position in shares of Corcept Therapeutics during the 3rd quarter worth approximately $294,000. AlphaCore Capital LLC acquired a new stake in Corcept Therapeutics in the 3rd quarter valued at approximately $390,000. Retirement Systems of Alabama acquired a new stake in Corcept Therapeutics in the 3rd quarter valued at approximately $11,306,000. Fulcrum Asset Management LLP increased its holdings in Corcept Therapeutics by 520.7% in the 3rd quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 479 shares during the last quarter. Finally, Brighton Jones LLC raised its position in Corcept Therapeutics by 51.9% in the third quarter. Brighton Jones LLC now owns 11,335 shares of the biotechnology company’s stock valued at $1,306,000 after purchasing an additional 3,872 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other Corcept Therapeutics news, Director James N. Wilson sold 10,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $110.69, for a total value of $1,106,900.00. Following the sale, the director owned 1,064,543 shares of the company’s stock, valued at $117,834,264.67. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David L. Mahoney sold 103,606 shares of Corcept Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $118.25, for a total value of $12,251,409.50. Following the completion of the transaction, the director owned 1,133,539 shares of the company’s stock, valued at $134,040,986.75. The trade was a 8.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 353,041 shares of company stock worth $40,016,889 over the last three months. Company insiders own 20.70% of the company’s stock.
Corcept Therapeutics Stock Down 1.0%
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.84 by $0.17. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The business had revenue of $340.47 million during the quarter, compared to the consensus estimate of $339.12 million. During the same quarter in the previous year, the firm posted $0.16 earnings per share. The company’s quarterly revenue was up 64.0% compared to the same quarter last year. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on CORT shares. HC Wainwright reissued a “buy” rating and issued a $165.00 target price on shares of Corcept Therapeutics in a research report on Friday, September 18th. Piper Sandler restated an “overweight” rating and set a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday, November 4th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research note on Monday, July 27th. Truist Financial began coverage on Corcept Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price objective for the company. Finally, Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Corcept Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $139.50.
View Our Latest Stock Analysis on Corcept Therapeutics
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Featured Articles
- Five stocks we like better than Corcept Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
